April 2018 in “Journal of Investigative Dermatology” Melanogenesis-related proteins may trigger immune responses in alopecia areata patients.
July 2024 in “Journal of Investigative Dermatology” CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
161 citations
,
March 1992 in “International Journal of Dermatology” Alopecia areata often starts before age 20, is more common in women, and may have a genetic link with other autoimmune diseases.
July 2024 in “Journal of Investigative Dermatology” JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
January 2025 in “Open Science Framework” AA-PRP temporarily increases hair density in androgenetic alopecia but loses effectiveness over time.
6 citations
,
November 2022 in “Journal of autoimmunity” JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
April 2023 in “Journal of Investigative Dermatology” Patients were very satisfied with the multidisciplinary group visit for alopecia areata.
9 citations
,
January 2010 in “International Journal of Trichology” The study found that the cause of alopecia areata can be identified through tissue analysis, and vertical sections are enough for diagnosis.
December 2025 in “Dermatology The American Medical Journal” JAK inhibitors are effective for long-term management of alopecia areata.
June 2025 in “British Journal of Dermatology” ALUDWIG can help standardize female hair loss assessment from a single image.
September 2023 in “Journal of the American Academy of Dermatology” Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.
29 citations
,
January 2003 in “Dermatology” The condition called 'acute diffuse and total alopecia of the female scalp' is actually a known condition named alopecia areata incognita.
April 2016 in “Journal of The American Academy of Dermatology” AGA patients have a lower quality of life than AA patients.
33 citations
,
October 2006 in “European Journal of Immunology” The CD44-CD49d complex boosts T cell activation and survival in autoimmune disease.
1 citations
,
August 2025 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” People with alopecia areata may have a higher risk of thyroid diseases.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
1 citations
,
April 2017 in “Journal of Dermatology and Dermatologic Surgery” IVIG therapy was linked to hair regrowth in two patients with hair loss, but it's not recommended due to its risks and costs.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
11 citations
,
June 2019 in “Journal of dermatology” New medicines that block a specific pathway are showing promise for treating severe hair loss but need more testing for safety and effectiveness.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
13 citations
,
January 2011 in “International Journal of Trichology” CTA is often mistaken for AA but doesn't respond to steroids and may require hair transplantation.
October 2021 in “Book Publisher International (a part of SCIENCEDOMAIN International)” The combination therapy of microdermabrasion and steroid injections is more effective for treating scalp Alopecia Areata than steroid injections alone.
56 citations
,
December 2011 in “The Plant Journal” AGD1 is important for root hair development in Arabidopsis, working with phosphoinositide signaling and the actin cytoskeleton.
18 citations
,
August 2012 in “Cutaneous and Ocular Toxicology” People with alopecia areata have higher insulin resistance.
IVL-DrugFluidic® can mass-produce high-quality, long-acting injectable drug microspheres, improving patient compliance and reducing side effects.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.